Navigation Links
Nanotechnology may lead to new treatment of liver cancer
Date:2/22/2011

Nanotechnology may open a new door on the treatment of liver cancer, according to a team of Penn State College of Medicine researchers. They used molecular-sized bubbles filled with chemotherapy drugs to prevent cell growth and initiate cell death in test tubes and mice.

Researchers evaluated the use of molecular-sized bubbles filled with C6-ceramide, called cerasomes, as an anti-cancer agent. Ceramide is a lipid molecule naturally present in the cell's plasma membrane and controls cell functions, including cell aging, or senescence.

Hepatocellular carcinoma is the fifth most common cancer in the world and is highly aggressive. The chance of surviving five years is less than five percent, and treatment is typically chemotherapy and surgical management including transplantation.

"The beauty of ceramide is that it is non-toxic to normal cells, putting them to sleep, while selectively killing cancer cells," said Mark Kester, Ph.D., G. Thomas Passananti Professor of Pharmacology.

Cerasomes, developed at Penn State College of Medicine, can target cancer cells very specifically and accurately, rather than affecting a larger area that includes healthy cells. The problem with ceramide is that as a lipid, it cannot be delivered effectively as a drug. To solve this limitation, the researchers use nanotechnology, creating the tiny cerasome, to turn the insoluble lipid into a soluble treatment.

"Cerasomes were designed as a therapeutic alternative to common chemotherapeutics," said Kester. "These have been shown to be toxic to cancer cells and not to normal cells, and have already been shown to effectively treat cellular and animal models of breast cancer and melanoma. Cerasomes have also been shown to be essentially free of toxic side effects normally associated with anticancer agents."

In the test tube and animal models of liver cancer, cerasomes, but not a placebo, selectively induced cell death in the cancer cells.

In mice with liver cancer, cerasomes blocked tumor vascularisation, the forming of blood vessels needed for growth and nutrition. Studies show that lack of nutrition causes cells to create more ceramide and leads to cell death.

"It is plausible that preventing liver tumor vascularization with cerasome treatment could induce widespread apoptosis, a genetically programmed series of events that leads to cell death in tumors," Kester said. "The efficacy of our cerasomes in the treatment of diverse cancers lends significant therapeutic promise as it translates from bench to bedside."

The researchers published their work in the journal Gut. A Penn State Dean's Feasibility Grant, Pennsylvania tobacco settlement funds, and the National Institutes of Health supported this work.

In an earlier study published in the journal Blood, researchers observed that cerasome use led to complete remission in aggressive, large granular lymphocytic leukemia in rats. In addition, the protein survivin, which prevents cell death, is heavily produced in NK-leukemia cells, but not in normal cells. Cerasome decreased expression of survivin and may lead to a therapeutic approach for fatal leukemia.


'/>"/>

Contact: Matt Solovey
msolovey@hmc.psu.edu
717-531-8606
Penn State
Source:Eurekalert

Related medicine news :

1. Nanotechnology and equity issues explored in new book
2. WUSTL awarded $18 million to treat heart, lungs with nanotechnology
3. UNC scientists receive grant to develop nanotechnology for pancreatic cancer diagnosis and treatment
4. NCI awards $13.6 million to UNCs Carolina Center of Cancer Nanotechnology Excellence
5. Novel nanotechnology collaboration leads to breakthrough in cancer research
6. Nanotechnology for water purification
7. Microfluidics Promotes Scientific University Research Using Nanotechnology with Innovation Incentives
8. Survey: Hiding risks can hurt public support for nanotechnology
9. Ross Nanotechnology Corporation Introduces the NeverWet™ Coating on its First Consumer Product – The Clear-n-Clean Plunger
10. New developments in nanotechnology tackle the 2 biggest problems associated with chemotherapy
11. Nanotechnology could help Arab region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... The Margarian Law Firm has ... contents of its ginger ale for allegedly containing no ginger. Dr. Pepper produces the ... Group, Inc., plaintiff Gegham Margaryan alleges Canada Dry Ginger Ale claims on its bottle ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... 21, 2017 , ... West Dermatology is pleased to announce the newest addition ... 2017, Ms. Vu will join West Dermatology’s large network of medical and cosmetic dermatology ... cancer , and more. She graduated from the University of Florida College of Medicine ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... why concussion rates are on the rise, say researchers presenting their work at ... Toronto, Ontario, Canada. , “The combination of evaluating the patterns of change in ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... bone marrow cancer that progresses rapidly without treatment. Newly diagnosed patients face intense ... chance of reoccurrence and relapse. With such a challenging diagnosis that requires ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... MINNEAPOLIS , July 5, 2017 Pace Analytical, a company of ... announcing today that they have acquired ESC Lab Sciences, further solidifying their position ... the United States . ... Steve Vanderboom- President and CEO of Pace Analytical ... of ESC Lab Sciences out of Mt Juliet, TN , ...
(Date:7/1/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today ... be broadcast live over the Internet on Thursday, July 27, ... the quarterly results will be made available at 7:30 a.m. ... The live audio webcast can be accessed via Zimmer Biomet,s ... archived for replay following the conference call. ...
(Date:6/30/2017)... Medical (AVACEN) announced the publication of new research in the peer-reviewed ... AVACEN Treatment Method to significantly reduce the widespread pain ... ... ... 200 to 400 million people worldwide according to The National Fibromyalgia ...
Breaking Medicine Technology: